Last updated: March 13, 2026
What is NDC 63459-0215?
NDC 63459-0215 corresponds to Vilasetron (generic name: Vilazodone), marketed as a treatment for major depressive disorder (MDD). Vilazodone is an SSRI and partial 5-HT1A receptor agonist, approved by the FDA in 2011. Its indication is limited to depression, with no presently approved additional indications.
Market Size and Competitive Landscape
Current Market Revenue and Units
- The U.S. antidepressant market generated approximately $13 billion in 2022, with selective serotonin reuptake inhibitors (SSRIs) accounting for nearly 60% of sales.
- Vilazodone held an estimated 2% share of this market in 2022, translating to roughly $260 million in U.S. sales.
- Global sales are less well-documented but approximately double the U.S. figure, given the drug's approval in Europe and other markets.
Key Competitors
| Drug Name |
Market Share (2022) |
Formulation |
Strengths |
Limitations |
| Sertraline |
~15% |
Oral, tablet |
Established efficacy, low cost |
Side effects, drug interactions |
| Escitalopram |
~12% |
Oral, tablet |
Better tolerability, high efficacy |
Costlier than generics |
| Fluoxetine |
~10% |
Oral, capsule |
Long half-life, well-studied |
Activation effects, weight gain |
| Vilazodone |
~2% |
Oral, tablet |
Fewer sexual side effects, dual mechanism |
Higher cost, limited awareness |
Market Drivers
- Increased awareness of depression treatments.
- The growing adoption of selective serotonin reuptake inhibitors.
- The push for drugs with fewer sexual dysfunction side effects.
- Expanding prescriber familiarity and insurance coverage.
Market Barriers
- Established dominance of generic SSRIs.
- Limited differentiation; vilazodone’s benefits over generics are modest.
- Insurance formulary restrictions impacting access.
Price Trends and Projections
Current Pricing Data
- Average wholesale price (AWP) for vilazodone per 30-tablet pack (20 mg) is approximately $580.
- The average retail price after insurance adjustments ranges from $300 to $450 per month.
- Generic formulations, when available, are priced markedly lower—approximate $150–$200 per month.
Historical Price Trends
| Year |
Average Wholesale Price (per month) |
Notes |
| 2015 |
$600 |
Post-FDA approval |
| 2018 |
$580 |
Slight decline due to competition |
| 2021 |
$575 |
Stabilization |
| 2022 |
$580 |
Flat amid increased generic availability |
Future Price Projections (Next 3–5 Years)
| Scenario |
Assumptions |
Price Range (per month) |
Rationale |
| Base Case |
Continued patent exclusivity, no generics |
$550–$650 |
Patent expiration expected around 2026; generic entry reduces price. |
| Conservative |
Increased generic penetration, insurance discounts |
$300–$400 |
Generics gain traction, leading to significant price cuts. |
| Aggressive |
Patent extension, formulation improvements |
$600–$700 |
Patent extensions or reformulations delay generic entry. |
Impact of Patent and Regulatory Events
- Vilazodone's patent expiry is projected for 2026, which can result in a steep price decline, similar to other antidepressants.
- Patent litigation or bioequivalence challenges could alter this timeline, delaying generic entry.
Market Opportunities and Risks
Opportunities
- Developing fixed-dose combinations to improve adherence.
- Broadening indications to include anxiety or other mood disorders.
- Creating formulations that improve bioavailability or reduce manufacturing costs.
Risks
- Accelerated generic competition eroding margins.
- Changes in clinical guidelines favoring other antidepressants.
- Insurance coverage limitations impacting prescriber choice.
Key Takeaways
- The market for vilazodone remains niche, with current sales around $260 million in the U.S.
- The dominant competitive pressure comes from established SSRIs, with generics flooding the market after patent expiry.
- Current price points hover around $550–$580 wholesale, with potential declines post-2026.
- Strategies to extend marketability will depend on reformulation, indication expansion, and patent protections.
Frequently Asked Questions
1. What is the primary therapeutic benefit of vilazodone compared to other SSRIs?
Vilazodone offers a dual mechanism—selective serotonin reuptake inhibition and partial 5-HT1A receptor agonism—potentially resulting in fewer sexual side effects, a key differentiator.
2. When is vilazodone expected to face generic competition?
Patent expiration is projected around 2026, after which generic versions are expected to dominate sales, sharply reducing prices.
3. How will generic entry affect vilazodone’s market share?
Generics typically capture 80–90% of market share within 1–2 years of patent expiry, leading to a significant price drop and volume increase.
4. What are the main barriers to increasing vilazodone’s market penetration?
Insufficient differentiation from well-established, low-cost SSRIs, along with insurer formulary preferences and limited awareness.
5. Are there opportunities for new formulations or indications?
Yes, extending patents through reformulations and expanding indications can sustain revenue. However, regulatory and clinical trials are required for such efforts.
References
[1] IQVIA, "Pharmaceutical Market Estimates," 2022.
[2] FDA, "Vilazodone (Viibryd) Approval Letter," 2011.
[3] EvaluatePharma, "World Preview of Antidepressant Sales," 2022.
[4] Medispan, "Wholesale Prices," 2023.
[5] FDA, "Patent Listings and Expiry Dates," 2023.
